Why Sarepta Therapeutics Inc. Shares Plunged Today

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of biopharmaceutical drugmaker Sarepta Therapeutics (NASDAQ: SRPT  ) plummeted 55% today after the Food and Drug Administration raised concerns about the trial results for its experimental Duchenne muscular dystrophy drug, eteplirsen.

So what: The FDA called Sarepta's application to sell eteplirsen "premature," suggesting that the company will need to spend more considerable time and money on the drug to address those concerns. In fact, the FDA's request for more data will delay the initiation of dosing in the confirmatory study until at least the second quarter of 2014 -- a particularly big deal for Sarepta, which has no other products in the market to help offset the cash burn.

Now what: Sarepta will follow up with the FDA this month to discuss the study's design.

"We strongly believe in the potential of eteplirsen to address a serious unmet medical need in DMD and we are committed to its development," Sarepta CEO Chris Garabedian said in a statement. "Our team at Sarepta recognizes the urgency of families who are seeking new treatments, and we will continue to work with the FDA on an acceptable confirmatory study design and, in parallel, seek to address their concerns regarding a potential NDA filing based on our current dataset."

Given the extremely speculative nature of the stock, however, average investors would do well to remain on the sidelines. 

A big growth stock to check out instead
This incredible tech stock is growing twice as fast as Google and Facebook, and more than three times as fast as Amazon.com and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table, and why he's so confident this will be a huge winner in 2013 and beyond. Just click here to watch!


Read/Post Comments (1) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 12, 2013, at 3:13 PM, timc1981 wrote:

    Most analysts have downgraded this stock, and with good reason. Sarepta has never brought a drug to market in 30 years, and eteplirsen does not appear likely to be effective. I think this is a great example of a bubble stock that burst.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2722851, ~/Articles/ArticleHandler.aspx, 10/20/2014 4:13:24 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement